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S1. CELL SIGNALING BY RECEPTOR TYROSINE KINASES:
FROM BASIC CONCEPTS TO CLINICAL APPLICATIONS
Joseph Schlessinger. Yale University School of Medicine, Department
of Pharmacology, P.O. Box 208066 New Haven, CT 06520, USA.
Receptor tyrosine kinases (RTKs) comprise a large family of cell
surface receptors that control many critical cellular processes.
The intrinsic protein kinase activity of RTKs is stimulated follow-
ing growth factor binding to the extracellular ligand-binding
domain which stimulates receptor dimerization, tyrosine auto-
phosphorylation and enhancement of enzymatic activity leading
to the recruitment and activation of multiple intracellular signal-
ing pathways. It is now well established that various human dis-
eases and pathologies are caused by dysfunction in RTKs or in the
intracellular signaling pathways that they activate. These include
many cancers, developmental abnormalities, sever bone disor-
ders, immune diseases, arteriosclerosis and angiogenesis among
others.
We have used mass spectrometry and X-ray crystallography to
demonstrate that tyrosine autophosphorylation of the catalytic
tyrosine kinase domain of FGF-receptor-1 (FGFR1) is mediated
by a sequential and precisely ordered reaction. We also demon-
strate that the rate of catalysis of two FGFR substrates is
enhanced by 50–100-fold following autophosphorylation of the
first site in the activation loop while autophosphorylation of the
second site in the activation loop results in 500–1000-fold increase
in the rate of substrate phosphorylation. We propose that FGFR1
is activated by a two-step mechanism mediated by strictly
ordered and regulated autophosphorylation suggesting that dis-
tinct phosphorylation states may provide both temporal and spa-
tial resolution to receptor signaling. Genetic models in mice
provide new opportunities for exploring and developing new
treatments for diseases caused by dysfunctions in RTKs and in
their intracellular signaling pathways. Inhibitors of tyrosine
kinases have been successfully applied for the treatment of can-
cers driven by activated tyrosine kinases. Sutent/SU11248 is a
new drug that blocks the actions of several tyrosine kinases
including c-Kit, PDGFR and VEGFR. Sutent has been approved by
the FDA for the treatment of gastrointestinal stromal tumors
(GIST), Gleevec resistant GIST, advanced kidney cancers as well
as other cancers. The approval marks the first time the FDA has
approved a new oncology product for two indications simulta-
neously. Finally, a novel scaffold-based drug discovery approach
will be described that enables the development of many new fam-
ilies of inhibitors for protein kinases and other enzymes that play
a role in cell signaling.
doi:10.1016/j.ejcsup.2006.04.134
S2. Src-FROM ONCOGENE TO CLINICAL TARGET
Justin M. Summy, Michael J. Gray, Gary E. Gallick. Department of
Cancer Biology, University of Texas, M.D. Anderson Cancer Center, TX,
United States.
The protein tyrosine kinase, Src, is the founding member of a
nine-gene family that regulates such diverse processes as prolif-
eration, migration, invasion, cell survival and angiogenesis. Aber-
rantly high Src activity is seen in numerous human tumors, with
increases in Src activity associated with progressive stages of dis-
ease and poor prognosis. In mouse models for several types of
human tumors, we demonstrate that Src activation increases
metastatic potential with limited effects on primary tumor
growth. In these models, pharmacologic inhibitors of Src retard
growth of large tumors and inhibit the development of metasta-
ses. Therefore, small molecule Src-selective inhibitors are now
in clinical trial in advanced stages of a number of solid tumors.
However, given its diverse modifications, Src itself may not repre-
sent the best marker for effectiveness of these therapeutic agents.
Therefore, we have examined Src signaling pathways that pro-
mote tumor progression, with an emphasis on pro-angiogenic
pathways. Src regulates expression of vascular endothelial
growth factor (VEGF) by activating Akt, p38 and STAT3. In
addition, Src regulates IL-8 expression in a pathway requiring
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p38 and STAT3 activation that is NFjB-independent. We demon-
strate further that Src activation contributes to the expression
of the transcriptional repressor, Id2 (Inhibitor of differentiation
2), expressed in pancreatic (and some other) tumor cells but not
in normal adult cells. Expression of Id-2 is regulated transcrip-
tionally by Hif-1a, and, in turn, Id-2 regulates Hif-1a stability,
thereby contributing to increased expression of VEGF in tumor
cells. These results suggest that Src activation deregulates multi-
ple pro-angiogenic programs that may provide markers as well as
targets for novel therapies.
doi:10.1016/j.ejcsup.2006.04.003
S3. AP-1-DEPENDENT GENE EXPRESSION DURING SKIN
TUMOURIGENESIS
Peter Angel. Deutsches Krebsforschungszentrum, Division Signal
Transduction and Growth Control, Heidelberg, Germany.
The transcription factor AP-1, which is composed of members of
the Fos, Jun and ATF protein families participates in physiologi-
cal and pathophysiological processes due to its central role as a
cellular switch of genetic programs in response to extracellular
signals. The distinct expression pattern of AP-1 subunits in the
skin, the loss of chemically induced carcinogenesis in AP-1 com-
promised mice, and the large number of putative AP-1 target
genes in epidermal cells, indicate that AP-1 members play a piv-
otal role in epidermal organisation, skin homeostasis and tumo-
urigenesis. To define AP-1-dependent genetic programs
associated with distinct stages of tumourigenesis in vivo we
have combined the well-established chemically induced mouse
model of epithelial skin tumours and comprehensive expression
profiling. A series of novel tumour-associated genes could be
identified including previously unrecognized molecules involved
in protein trafficking and novel serine and aspartic proteases,
which are expressed depending on the differentiation and pro-
gression state of the tumours. Moreover, four members of the
S100 family of Ca2+ binding proteins, S100A3, A6 and A8, A9 were
identified, which are differentially expressed in murine and
human epithelial tumours of the skin and other organs. These
molecules are part of a novel signalling pathway controlling
AP-1 and NFjB-dependent genetic programs, which are likely
to play an important role in tumour formation, progression
and metastasis.
doi:10.1016/j.ejcsup.2006.04.004
S4. ENZASTAURIN – FROM BENCH TO BEDSIDE, AND BACK
Manfred Lehnert. Eli Lilly and Company, Oncology Platform Team,
Indianapolis, IN, USA.
Enzastaurin is an oral serine-threonine kinase inhibitor of the
PI3K signaling pathway and PKCb. In preclinical in vitro and
in vivo tumor models, enzastaurin promotes apoptosis, inhibits
tumor cell proliferation and blocks tumor-induced angiogenesis.
Phase II studies showed encouraging efficacy in heavily pre-
treated patients with glioblastoma multiforme and diffuse large
B cell lymphomas, respectively. Prospective randomized phase
III trials are about to commence in these two tumor types. Phase
II trials are in progress or development in a variety of cancers,
including breast, ovarian, colon, prostate, non-small cell lung
cancer, chronic lymphocytic leukemia and follicular lymphomas.
The available safety data show good tolerance of enzastaurin
when used as a single agent. Phase I studies in combination with
various cancer agents, cytotoxic as well as biologically targeted,
are in progress. Most enzastaurin trials include tumor tissue col-
lection for correlative analysis of candidate biomarkers and clin-
ical outcome. We hope this will allow selection of those cancer
patients in the future who gain most benefit from enzastaurin
treatment.
doi:10.1016/j.ejcsup.2006.04.005
S5. SURVIVING AND TRANSFORMING GROWTH FACTOR BETA
(TGF-b) AS DRUG TARGETS IN CANCER
Michael Lahn. Oncology Therapeutic Area, Lilly Research Laboratories,
Indianapolis, IN, USA.
The molecular heterogeneity of malignant cells and their interac-
tion with the surrounding microenvironment is one of the most
challenging aspects of drug development in oncology. Developing
successful drug intervention strategies requires the identification
of molecular targets that show high impact on either tumor cell
growth or the supporting microenvironment. In recent years, sev-
eral such targets have been proposed, including Survivin and
TGF-b. Survivin is uniquely upregulated in most cancer cells,
while in non-malignant cells it is generally not expressed. Thus,
an inhibition of Survivin could lead to a selective treatment of
malignant cells without affecting normal tissue cells. Because of
its structure, selective small molecule inhibitors are difficult to
identify.
In collaboration with Isis Pharmaceuticals (Carlsbad, CA, USA)
Eli Lilly and Company (Indianapolis, IN, USA) (Lilly) developed a
second generation antisense oligonucleotide (ASO) that is specific
for the inhibition of Survivin in cells. This ASO against Survivin
has been evaluated in various non-clinical in vitro and in vivo
models confirming its specificity. Based on this information, a
phase I clinical trial was started to evaluate its safety and phar-
macokinetic profile in cancer patients. In contrast to a target in
cancer cells, inhibiting TGF-b signaling is designed to modulate
the microenvironment of cancer cells. Lilly developed various
small molecule inhibitors for the TGF-b receptor type I (TGF-
bRI) kinase. From this series of molecules, one inhibitor has been
selected for clinical investigation. The compound LY2157299 has
demonstrated anti-tumor activity in various non-clinical
in vitro and in vivo models, supporting its evaluation in a phase
I clinical trial of patients with cancer. In summary, Lilly has a
comprehensive program to develop inhibitors of tumor cells
and their supporting microenvironment, such as Survivin and
TGF-b.
doi:10.1016/j.ejcsup.2006.04.006
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